Published Paper Details:

Neurodegenerative diseases, such as Alzheimer's disease (AD) and Parkinson's disease (PD), cause significant impairment by affecting neurons in the central nervous system (CNS). These conditions lead to progressive nerve cell degeneration and death, resulting in movement disorders like ataxia and cognitive impairments such as dementia. AD alone accounts for 60-70% of dementia cases worldwide.A growing body of research highlights a link between neurodegenerative and metabolic disorders. Insulin signaling abnormalities, common in older adults with pre-diabetes or type 2 diabetes mellitus (T2DM), are also observed in AD and PD. Although the exact mechanisms connecting these disorders remain unclear, shared pathological features such as inflammation, insulin resistance, and oxidative stress suggest a common link. This overlap has spurred interest in repurposing antidiabetic drugs for treating neurodegenerative diseases.Antidiabetic medications, particularly those targeting insulin resistance and inflammation, offer potential as disease-modifying treatments for AD and PD. Despite the challenges in developing effective therapies for these neurodegenerative conditions, exploring the use of antidiabetic drugs presents a promising avenue for future research and therapeutic strategies. This review focuses on the potential of repurposing antidiabetic treatments to manage and possibly alter the course of AD and PD.